S Del Prato, RJ Heine, L Keilson, C Guitard … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Retrospective subgroup analyses were performed on
pooled data from all completed nateglinide studies (12 randomized, double blind
trials and 1 open trial) in patients with type 2 diabetes. A total of 3,702 ... Cited by 26 - Related articles - BL Direct - All 5 versions
RJ Heine, L Keilson, C Guitard, SG Shen, … - Diabetes Care, 2003 - Am Diabetes Assoc Experience from nateglinide pooled database retrospective analysis ... S TEFANO
D EL P RATO , MD 1 R OBERT J. H EINE , MD , PHD 2 L EONARD K EILSON , MD , MPH 3 ... C HRISTIANE G UITARD , MD 4 S HARON G. S HEN , PHD 5 R EBECCA P. E ... Related articles
- ►diabetesjournals.org C Hasslacher - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—The type and severity of adverse events during repaglinide treatment
were similar to the run-in period. The number of patients with adverse events
was not significantly related to renal function during run-in or ... Cited by 21 - Related articles - BL Direct - All 6 versions
ES Horton, JE Foley, SG Shen, MA Baron - Current Medical Research and Opinion®, 2004 - informahealthcare.com Objective: To assess the efficacy and tolerability of the combination of
nateglinide (120 mg, ac) and metformin (500 mg, tid) as initial treatment in
drug-naïve patients with type 2 diabetes mellitus (T2DM). Research design ... Cited by 19 - Related articles - BL Direct - All 7 versions
- Free from Publisher GS Meneilly, D Elahi - Diabetes Care, 2005 - Am Diabetes Assoc Numerous studies (1–6) have systematically examined the metabolic alterations
that occur in middle-aged patients with type 2 diabetes. These studies have
found that when compared with age- and weight-matched control subjects, ... Cited by 13 - Related articles - All 5 versions
R Friedman, JL Gross - Diabetes care, 1991 - Am Diabetes Assoc OBJECTIVE: To evaluate, by means of a precise method, the rate of decline of
glomerular filtration rate in proteinuric non-insulin-dependent diabetic (NIDDM)
patients. RESEARCH DESIGN AND METHODS: The study was comprised of seven ... Cited by 13 - Related articles - All 5 versions
- ►diabetesjournals.org V Fonseca, G Grunberger, S Gupta, S Shen, … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—In placebo-treated patients, HbA 1c did not change (Δ = 0.0 ± 0.1%).
In patients randomized to nateglinide, HbA 1c decreased from 8.3 to 7.5% (Δ =
−0.8 ± 0.1%, P < 0.0001 vs. placebo). Target HbA 1c (<7.0%) was achieved ... Cited by 35 - Related articles - BL Direct - All 9 versions
AH Barnett, DM Anderson, S Shelley, R … - Diabetes Obesity and Metabolism, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 14 - Related articles - BL Direct - All 3 versions
- ►oxfordjournals.org P Gaede, HP Hansen, HH Parving, O … - Nephrology Dialysis Transplantation, 2003 - ERA-EDTA Background. Low-dose treatment with acetylsalicylic acid (ASA) is widely
recommended to type 2 diabetic patients as primary prevention against
cardiovascular disease. High-dose treatment with cyclooxygenase inhibitors ... Cited by 14 - Related articles - BL Direct - All 4 versions
AJ Nicholls - Diabetic medicine, 2002 - interscience.wiley.com Atherosclerotic renovascular disease (ARVD) is common in thegeneral population,
and its prevalence increases with age. Parallelstudies show it is also common in
patients with diabetes. The widespreaduse of angiotensin converting enzyme ... Cited by 14 - Related articles - BL Direct - All 6 versions
